 |
1 Product |  |
19 Diseases | | 1 Product |
|
1 Trial |  |
63 News |  |
- | Capoxigem (apricoxib) / Adastra Pharma
Retrospective data, Journal: Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy "Moroccan experience". (Pubmed Central) - Apr 5, 2024
In the United States, both ASTRO and the NCCN recognize SBRT as a valid treatment option for localized CaP. Ongoing phase III trials are being conducted to further substantiate these long-term results and to establish SBRT as the future standard of care for localized CaP.
- || Capoxigem (apricoxib) / Adastra Pharma, TG01 vaccine / Circio Holding
Enrollment open: The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma (clinicaltrials.gov) - Nov 3, 2023
P1/2, N=20, Recruiting, Sponsor: Oslo University Hospital
Ongoing phase III trials are being conducted to further substantiate these long-term results and to establish SBRT as the future standard of care for localized CaP. Not yet recruiting --> Recruiting
- ||| Capoxigem (apricoxib) / Adastra Pharma, balstilimab (AGEN2034) / Agenus, Recepta
Clinical: Neat study @Aiims1742 @DrShubhamPant @EileenMOReilly . We have a similar study targeting MRD in resected RAS mutated #pancreatic with vaccine TG01/QS-21 +/-balstilimab: A randomized phase 2 study (TESLA). Presenting at #ASCO23 https://t.co/2Y7Z6110AO (Twitter) - May 29, 2023
- TG01-STUDY: A PHASE 1/2 STUDY WITH TG01 IMMUNOTHERAPY VACCINATION IN PATIENTS WITH CONFIRMED NRAS/KRAS MUTATION ON CODON 12/13 AND MULTIPLE MYELOMA OR HIGH-RISK SMOLDERING MYELOMA. () - May 12, 2023 - Abstract #EHA2023EHA_3001;
Results from this trial will provide insights into a new possible treatment for patientswith MM and SMM. Summary/
- || Capoxigem (apricoxib) / Adastra Pharma, TG01 vaccine / Circio Holding
New P1/2 trial: The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma (clinicaltrials.gov) - May 3, 2023
P1/2, N=20, Not yet recruiting, Sponsor: Oslo University Hospital
- TG01 vaccine / Targovax, balstilimab (AGEN2034) / Agenus, Recepta
Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA). (On Demand | Hall A; Poster Bd # 509a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1329;
P2
Br J Cancer 2020 122:971-77. Clinical trial information: NCT05638698.
- ||| Capoxigem (apricoxib) / Adastra Pharma, balstilimab (AGEN2034) / Agenus, Recepta
@circio_asa #ASCO23 poster #PancreaticCancer #balstilimab #TG01 https://t.co/4FRYimg5wv (Twitter) - Apr 26, 2023
- ||||| Capoxigem (apricoxib) / Adastra Pharma, balstilimab (AGEN2034) / Agenus, Recepta
Clinical, Checkpoint inhibition, IO biomarker: 1st patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the US. The study is being led by KU Cancer Center investigator Dr. @anup_kasi. https://t.co/WhN2bcKSe6 (Twitter) - Mar 14, 2023
- |||| Capoxigem (apricoxib) / Adastra Pharma
Review: What a great study by the RPCI group! With max doses suggested by NRG, Timmerman, UK SABR, AAPM TG101 and others, risks are ~10%. A systematic review on brachial plexopathy after SBRT will be coming out in RedJ soon (too late to be in HyTEC and too soon for this study I guess!) (Twitter) - Dec 30, 2022
- | Capoxigem (apricoxib) / Adastra Pharma
Preclinical, Journal: Bona fide atypical scrapie faithfully reproduced for the first time in a rodent model. (Pubmed Central) - Dec 16, 2022
Our analysis of the results of these bioassays concludes that the strain generated in this model is indistinguishable to that causing atypical scrapie (Nor98). Thus, we present the first faithful model for a bona fide, transmissible, ovine, atypical scrapie prion disease.
- Capoxigem (apricoxib) / Adastra Pharma
Extracting Organ-Specific Radiobiological Model Parameters of Abdominal Organs from Clinical Outcome Data for Biological Radiation Treatment Planning (Henry B. Gonzalez Convention Center, Exhibit Hall 1) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_1090;
We developed a robust method to successfully extract abdominal organ-specific radiobiological parameters from clinical data. These parameters can be used to convert OAR dose constraints from different RT fractionations/techniques for biologically optimized RT planning
- | Capoxigem (apricoxib) / Adastra Pharma, zotiraciclib (TG02) / Adastra Pharma
Preclinical, Journal: Overexpression of Oil Palm Early Nodulin 93 Protein Gene (EgENOD93) Enhances In Vitro Shoot Regeneration in Arabidopsis thaliana. (Pubmed Central) - Jun 25, 2022
This together with the previous results observed in oil palm and Medicago truncatula suggests that ENOD93 plays a key role in the induction of somatic embryogenesis. A similarity to early nodulation-like ontogeny is possible.
- | Capoxigem (apricoxib) / Adastra Pharma, zotiraciclib (TG02) / Adastra Pharma
Journal: Identification and Characterization of a Multifunctional Biocontrol Agent, Streptomyces griseorubiginosus LJS06, Against Cucumber Anthracnose. (Pubmed Central) - Jun 22, 2022
In addition, the spraying and drenching of diluted SL06 before inoculation consistently and significantly (p < 0.05) reduced anthracnose severity. These results jointly suggest that S. griseorubiginosus LJS06 can aid in the management of cucumber anthracnose by directly inhibiting conidial function and priming the plant defense system.
- || Capoxigem (apricoxib) / Adastra Pharma
P1 data, Journal: LITE SABR M1: Planning design and dosimetric endpoints for a phase I trial of lattice SBRT. (Pubmed Central) - Apr 20, 2022
P=N/A
Lattice SBRT planning techniques produce consistent and efficient treatment plans. Refined techniques described here further improve the quality of the planning technique.
- | Capoxigem (apricoxib) / Adastra Pharma
Preclinical, Journal: Porcine Prion Protein as a Paradigm of Limited Susceptibility to Prion Strain Propagation. (Pubmed Central) - Feb 11, 2022
Bioassay proved that PoPrP-Tg001-mice were susceptible only to the classic BSE agent, and PMCA results indicate that only classic BSE can convert pig-PrPC into scrapie-type PrP (PrPSc), independently of the species origin. Therefore, conformational flexibility constraints associated with pig-PrP would limit the number of permissible PrPSc conformations compatible with pig-PrPC, thus suggesting that pig-PrPC may constitute a paradigm of low conformational flexibility that could confer high resistance to the diversity of prion strains.
- Capoxigem (apricoxib) / Adastra Pharma
[VIRTUAL] Dosimetric Comparison of Single-Isocenter and Multiple-Isocenter Techniques for Two-Lesion Lung SBRT Using the RefleXion High-Speed Ring-Gantry System (McCormick Place West, Outside Room W375) - Oct 30, 2021 - Abstract #ASTRO2021ASTRO_608;
This study shows that a single-isocenter technique for the scenario of two lung lesions is dosimetrically feasible and clinically efficient with the RefleXion X1 in SBRT mode. Single-isocenter treatment delivery techniques may be a desirable option for efficient radio-ablative therapies directed at multiple metastatic targets.
- | Capoxigem (apricoxib) / Adastra Pharma
Journal: Dosimetric Comparison of Single-Isocenter and Multiple-Isocenter Techniques for Two-Lesion Lung SBRT Using the RefleXion High-Speed Ring-Gantry System. (Pubmed Central) - Oct 29, 2021
This study shows that a single-isocenter technique for the scenario of two lung lesions is dosimetrically feasible and clinically efficient with the RefleXion X1 in SBRT mode. Single-isocenter treatment delivery techniques may be a desirable option for efficient radio-ablative therapies directed at multiple metastatic targets.
- || Capoxigem (apricoxib) / Adastra Pharma
The point is that TG101 is at best a conservative guess it’s not gospel. For TGN, I use the gammaknife, stereotactic frame and a prescription dose of 37.5 Gy to the 50% isodose line (single 4 mm shot). The 50% line touches the brainstem. (Twitter) - Sep 18, 2021
- || Capoxigem (apricoxib) / Adastra Pharma
TG101 is very conservative for point doses. You can’t use that for justification here. (Twitter) - Sep 18, 2021
- ||| Capoxigem (apricoxib) / Adastra Pharma
Sorry should have clarified: Dmax(<0.035cc) <14 Gy (which is 1 Gy lower than TG101 recommends). We prescribe to 100% IDL. There might need to be some coverage compromise to meet this constraint. If this is not feasible, could try 17 Gy or 16 Gy to tumor, but I wouldn't go lower. (Twitter) - Sep 17, 2021
- | Capoxigem (apricoxib) / Adastra Pharma
Preclinical, Journal: Learning Deficits Accompanied by Microglial Proliferation After the Long-Term Post-Injection of Alzheimer's Disease Brain Extract in Mouse Brains. (Pubmed Central) - Sep 17, 2021
Single-isocenter treatment delivery techniques may be a desirable option for efficient radio-ablative therapies directed at multiple metastatic targets. These results potentially implicate tau propagation in functional decline and indicate that long-term changes in non-mutated tau mice may reflect human pathological conditions.
- || Capoxigem (apricoxib) / Adastra Pharma
This is fascinating. The Timmerman sheet (>34%) beats HyTEC and TG101. It tells you something very powerful about the desperate need for simplicity, practicality, efficiency, translatability in all of this. #radonc #jc (Twitter) - Jun 19, 2021
- | Capoxigem (apricoxib) / Adastra Pharma
Journal: Distribution of Zinc in Mycelial Cells and Antioxidant and Anti-Inflammatory Activities of Mycelia Zinc Polysaccharides from Thelephora ganbajun TG-01. (Pubmed Central) - May 6, 2021
By establishing zebrafish models, we found that MZPS-2 can significantly scavenge free radicals, reduce the generation of reactive oxygen species caused by inflammation, and inhibit the recruitment of neutrophils toward the injury site. Therefore, MZPS-2 exhibited antioxidant and anti-inflammatory effects and can be used as a zinc supplement with specific biological activities to alleviate zinc deficiency complications, such as chronic oxidative stress or inflammation.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lucentis (ranibizumab) / Roche, Novartis
Journal: Identification of potential candidate genes for lip and oral cavity cancer using network analysis. (Pubmed Central) - Apr 13, 2021
Gene enrichment analysis was also performed to identify the gene ontology categorization of cellular components, biological processes, molecular functions, and biological pathways. The genes identified in this study could furnish a new understanding of the underlying molecular mechanisms of carcinogenesis and provide more reliable biomarkers for early diagnosis, prognostication, and treatment of lip and oral cavity cancer.
- | Capoxigem (apricoxib) / Adastra Pharma
Preclinical, Journal: MicroRNA Alterations in a Tg501 Mouse Model of Prion Disease. (Pubmed Central) - Apr 2, 2021
Minimal changes observed before the disease onset suggests that most miRNA alterations observed here are driven by advanced prion-associated pathology, possibly limiting their use as diagnostic markers. However, the results encourage further mechanistic studies on miRNA-regulated pathways involved in these neurodegenerative conditions.
- || Capoxigem (apricoxib) / Adastra Pharma
Clinical, P1/2 data, Journal, IO biomarker: TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. (Pubmed Central) - Jan 16, 2021
P1/2
TG01/GM-CSF with gemcitabine was well tolerated, with high levels of immune activation. OS and DFS compare favourably with published data for adjuvant gemcitabine.
- | Capoxigem (apricoxib) / Adastra Pharma, zotiraciclib (TG02) / Adastra Pharma
Journal: Antibacterial Activity of Fruiting Body Extracts from Culinary-Medicinal Winter Mushroom, Flammulina velutipes (Agaricomycetes) against Oral Pathogen Streptococcus mutans. (Pubmed Central) - Dec 20, 2020
Thus, F. velutipes extracts can effectively inhibit the growth of the oral pathogen S. mutans without cytotoxicity against human oral keratinocytes. Therefore, F. velutipes is a good candidate for the development of oral hygiene agents to control dental caries.
- Capoxigem (apricoxib) / Adastra Pharma, gemcitabine / Generic mfg.
Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01) (Room B) - Oct 29, 2019 - Abstract #ESMOIO2019ESMO_IO_212;
P1/2
Single mutation vaccines and small molecules targeting single mutations are therefore unlikely to be effective while therapies targeting a mix of KRAS mutations (TG01) may be more beneficial.Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- | Capoxigem (apricoxib) / Tragara
Journal: The potential application of biosurfactant produced by Pseudomonas aeruginosa TGC01 using crude glycerol on the enzymatic hydrolysis of lignocellulosic material. (Pubmed Central) - Oct 12, 2019
Biosurfactant increased the glucose released in the enzymatic hydrolysis in relation to control (without tensoactive) when WOP (19% increase) and NP (113% increase) were used. The process for NP (18% lignin) was economical, given that the biosurfactant present made a delignification process unnecessary.
- Capoxigem (apricoxib) / Tragara
Divergent fates of antigen-specific CD8+ T cell clones in mice with acute myeloid leukemia (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_914;
However, the nature of the leukemia antigen and the context in which it is presented are critical factors in dictating the underlying mechanism of tolerance that ensues. A search for the Tg101 antigen and investigation of the epigenetic landscape of naive versus tolerized Tg101 T cells are ongoing.
- Capoxigem (apricoxib) / Tragara
Dosimetric Comparison of Robotic Radiosurgery and VMAT Delivering Stereotactic Ablative Body Radiation Therapy to Small Renal Cancer (ASTRO Innovation Hub) - Sep 24, 2019 - Abstract #ASTRO2019ASTRO_4338;
For institutions where robotic radiosurgery and VMAT are both available, robotic radiosurgery might be a better choice to deliver SABR to small renal cancer. Table: The dosimetric parameters of robotic radiosurgery and VMAT plans Parameters (median) CK VMAT p value PTV V100% 95.43 95.00 0.333 GTV V100% 100.00 100.00 0.273 CI 1.16 1.22 0.153 HI 1.30 1.24 0.074 D10cc-stomach (cGy) 934.25 529.13 0.144 D5cc-stomach (cGy) 1049.00 594.79 0.144 Dmax-intestine (cGy) 1183.81 1513.95 0.007 D20cc- intestine (cGy) 619.35 681.30 0.878 D10cc- intestine (cGy) 719.10 898.33 0.093 D5cc-bowel (cGy) 802.05 1040.00 0.013 Dmax-colon (cGy) 1706.27 1923.95 0.050 D20cc-colon (cGy) 758.20 658.34 0.889 D10cc-colon (cGy) 895.25 981.08 0.327 D5cc-colon (cGy) 987.60 1130.24 0.123 D700cc-liver (cGy) 44.10 6.18 0.008 Dmean-liver (cGy) 106.34 75.00 0.005 D1cc-Cord (cGy) 426.40 536.15 0.203 D0.5cc-Cord (cGy) 463.35 558.44 0.241 Dmax-Cord (cGy) 547.42 609.95 0.575 V14Gy-contralateral kidney (cGy) 0.00 0.00 1.000 Dmean-contralateral kidney (cGy) 92.63 148.21 0.878
- Capoxigem (apricoxib) / Tragara
Risk of Vertebral Fracture and Local Recurrence after Palliative Spine Stereotatic Body Radiotherapy (SBRT). (ASTRO Innovation Hub) - Sep 24, 2019 - Abstract #ASTRO2019ASTRO_3145;
Treatments typically exceeded TG101 guideline spinal cord “threshold doses”, while respecting maximum point doses, for the spinal cord without evidence of symptomatic myelitis. These results show superior FFFR and FFLR than prior reported studies and supports increasing use of SBRT in a wide range of patients.
- Capoxigem (apricoxib) / Tragara
Spinal Cord Tolerance Guided by Stereotactic Radiosurgical Treatment of Intramedullary Arteriovenous Malformations (ASTRO Innovation Hub) - Sep 24, 2019 - Abstract #ASTRO2019ASTRO_3141;
Further, all patients exceeded volumetric constraints to cord. Most exceeded volumetric constraints to CmA, as well.
- Capoxigem (apricoxib) / Adastra Pharma
Enrollment change: Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 19, 2019
P=N/A, N=1, Terminated, Sponsor: Jonsson Comprehensive Cancer Center
Most exceeded volumetric constraints to CmA, as well. N=40 --> 1
- Capoxigem (apricoxib) / Adastra Pharma
Trial completion, P2 data, Combination therapy: 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 10, 2015
P2, N=109, Completed, Sponsor: Martin Edelman, MD
N=40 --> 1 Active, not recruiting --> Completed
- ||| Capoxigem (apricoxib) / Adastra Pharma
Enrollment closed, P2 data, Combination therapy: 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 30, 2012
P2, N=109, Active, not recruiting, Sponsor: Martin Edelman, MD
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Capoxigem (apricoxib) / Adastra Pharma
Trial termination: Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=1, Terminated, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Terminated; Drug sponsor stopped drug manufacture due to toxicity issues from other studies
- |||| Capoxigem (apricoxib) / Adastra Pharma
Trial completion, Combination therapy, Metastases: APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 12, 2012
P2, N=109, Completed, Sponsor: Tragara Pharmaceuticals, Inc.
Recruiting --> Terminated; Drug sponsor stopped drug manufacture due to toxicity issues from other studies Active, not recruiting --> Completed
- |||| Capoxigem (apricoxib) / Adastra Pharma
Trial completion, Combination therapy: TP2001-201: APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 12, 2012
P2, N=120, Completed, Sponsor: Tragara Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Capoxigem (apricoxib) / Adastra Pharma
Enrollment change, Combination therapy: APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202) (clinicaltrials.gov) - Mar 12, 2012
P2, N=12, Terminated, Sponsor: Tragara Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=120 --> 12